P&G ready to assess Teva staffing; Congress to devote fall to healthcare, FDA;

> Watch out, Teva: Now that Procter & Gamble has bought the generics-maker and sold its Pringles business, it's time for HQ to take a look at staffing levels. Story

> The House Energy and Commerce Committee's Health panel will spend the fall focused on healthcare reform regulations and preparing for a major FDA bill. Story

> Dendreon ($DNDN) has canceled its $8.3-million contract with GlaxoSmithKline ($GSK) for high-volume manufacture of the lackluster cancer vaccine Provenge, but may still be on the hook for a monthly fee of $2 million for September and October for breaching a 60-day notice requirement. Story

> Roche has unveiled a desktop continuous-random-access analyzer of chemical and biochemical parameters in aqueous solutions, intended for metabolite screening and substrate analysis. Roche release

> Big 3 drug distributor AmerisourceBergen ($ABC) has acquired IntrinsiQ, an informatics solution provider that targets community oncologists to help them make treatment decisions for their patients. Release

> Lonza Group and Shanghai Fosun Pharmaceutical Group plan to invest $15.7 million to create a joint venture in Pudong Zhangjiang High-Tech Industry Zone. Item

> Xcelience, a leader in early drug development, has expanded its equipment arsenal for clinical trial supply manufacturing and packaging. Xcelience release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.